Marinus Pharmaceuticals reported $92.33M in Cash and Equivalent for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 139.83M 65.09M
ALKERMES ALKS:US $ 254.65M 27.91M
Amgen AMGN:US $ 5203M 1325M
Aptinyx Inc APTX:US $ 85.27M 14.89M
Biogen BIIB:US $ 2646.6M 897.3M
Eisai 4523:JP Y 287815M 23426M
Enanta Pharmaceuticals ENTA:US $ 28.37M 12.62M
Esperion Therapeutics ESPR:US $ 122.94M 27.42M
Gilead Sciences GILD:US $ 7000M 2704M
Intercept Pharmaceuticals ICPT:US $ 58.02M 9.7M
Intra Cellular Therapies ITCI:US $ 77.24M 52.06M
Marinus Pharmaceuticals MRNS:US $ 92.33M 33.99M
Minerva Neurosciences NERV:US $ 49.75M 5.19M
Neurocrine Biosciences NBIX:US $ 163.3M 106.9M
Ptc Therapeutics PTCT:US $ 158.16M 13.98M
Regeneron Pharmaceuticals REGN:US $ 3395.1M 49.4M
Sarepta Therapeutics SRPT:US $ 868.56M 365.31M
Supernus Pharmaceuticals SUPN:US $ 173.43M 57.71M
Vertex Pharmaceuticals VRTX:US $ 8702.2M 1102.1M
YTE INCY:US $ 2435.38M 178.62M